Bionime Corporation (Taiwan, China)

1. Established in Apr. 2003, Bionime Corporation issued its stock in Aug. 2008. Its main products are blood glucose measurement machines and blood glucose measurement chips. a. the proportion of main products: blood glucose measurement machines (25% of total revenues), blood glucose measurement chips(73% of total revenues). b. the structure of the market: overseas sales accounts for 97%, domestic sales accounts for3%, of which the main export to Europe accounts for 54% , Asia 19% and Americas 17% 2. Blood glucose measurement machines of the main business are dominated by European and American factories, such as Roche (33%), Johnson & Johnson (27%), Abbott (15%), Bayer (14%), etc. The top four firms share 89% of the global market. Due to high technical threshold, there are only a few manufactures of Blood glucose measurement machines, such as Wuding, Taixin and Taibo, etc. which have experience of mass production. However, as international companies’ monopoly situation, Bionime Corporation’s turnover in 2007 was only approximately 600 million, accounting for 1% of the global market share. For domestic competition, Wuding’s turnover reached 10 billion, accounting for 2% of the global market share. Compared with that, Bionime Corporation is relatively smaller. 3. Business background: a. sources of technology: the company's director and General Manager - Qi Yu Qiao, Director and Deputy General Manager ? Jiang Tai Xiong, Senior Manager - Guo Jia Zhi all once served in the Palladium Medical Technology, which is mainly engaged in production of blood glucose measurement machines. B. There are 5 directors and 2 supervisors, holding 15% of the stock. The main shareholder Swiss Ypsomed hold 10% of the stock and Chairman Huang Chun Mu hold 6% of the stock